You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial

Citation Tools

Article menu
Cardiovascular and metabolic risk
Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Shestakova M, Kvasnikov B, Erina E on behalf of the study investigators, et al
Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial
BMJ Open Diabetes Research and Care 2023;11:e003290. doi: 10.1136/bmjdrc-2022-003290